Effect of SGLT2 Inhibitors on Anemic CKD Patients

Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Inclusion Criteria:

• age more than 18 years
• CKD stage 1_4
• baseline hemoglobin 8.5 to 12.9 g/dl
• stable anemia regimen for more than 8 weeks

Exclusion Criteria:

• dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion